Stockman Wealth Management Inc. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 50.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,527 shares of the biopharmaceutical company’s stock after selling 26,503 shares during the period. Gilead Sciences comprises 1.8% of Stockman Wealth Management Inc.’s holdings, making the stock its 16th largest holding. Stockman Wealth Management Inc.’s holdings in Gilead Sciences were worth $1,807,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the business. Keel Point LLC lifted its holdings in shares of Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 11 shares during the period. West Oak Capital LLC lifted its holdings in shares of Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after acquiring an additional 32 shares during the period. First Heartland Consultants Inc. lifted its holdings in shares of Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after acquiring an additional 39 shares during the period. Arrow Financial Corp lifted its holdings in shares of Gilead Sciences by 0.3% during the 2nd quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 45 shares during the period. Finally, Westover Capital Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.8% during the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after acquiring an additional 46 shares during the period. Hedge funds and other institutional investors own 74.38% of the company’s stock.
Several equities analysts recently commented on the stock. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Thursday, August 31st. Deutsche Bank AG reissued a “buy” rating and issued a $81.00 price objective on shares of Gilead Sciences in a research note on Thursday, August 31st. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective for the company in a research note on Friday, October 13th. Credit Suisse Group reissued an “outperform” rating and issued a $85.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $85.92.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/stockman-wealth-management-inc-has-1-81-million-holdings-in-gilead-sciences-inc-gild.html.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $73.77 on Friday. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27. The company has a market cap of $96,363.46, a PE ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 4.74 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the prior year, the firm posted $2.75 EPS. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. equities analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.82%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.69%.
In other news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 50,000 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the completion of the transaction, the executive vice president now owns 113,237 shares in the company, valued at approximately $8,945,723. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 446,819 shares of company stock worth $36,269,486. Insiders own 1.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.